撰文丨王聪 编辑丨王多鱼 排版丨水成文 自 2017 年起，美国 FDA 陆续批准了多款 CAR-T 细胞疗法 上市，用于治疗白血病、淋巴瘤等血液类癌 症，并展现了强大的治疗效果。 近年来，CAR-T 细胞疗法在临床研究中显示出对 系统性红斑狼疮、系统性硬化症、特发性炎性肌病、重 症肌无力 、 免疫介导的坏死性肌病 等 B 细胞介导的 自身免疫疾病 具有良好的治疗效果。 2026 年 2 月 5 日，国际顶尖医学期刊 Nature Medicine 上发表了一篇题为： Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases 的研究论文。 中位随访时间为 16.5 个月 （范围为 9 - 24 个月） ，所有患者均出现了临床显著的自身免疫疾病的改善 或缓解，表现为疾病活动评分降低以及器官损伤逆转的迹象。这一改善使得即使在 B 细胞重建之后，也能 持续停用免疫调节剂。 基于上述试验结果，研究团队表示，迫切需要启动纳入儿童和青少年的正式临床试验，以确认这些初步结 果，并评估这种 CAR-T ...

Core Insights - The study published in Nature reveals that fibroblastic reticular cells (FRC) guide the initiation of T cell responses via CD44, and that cytomegalovirus (CMV) can disrupt this process by producing the m11 protein, which interferes with CD44 function, thereby weakening antiviral responses [4][11]. Group 1: Mechanism of Immune Response - FRC networks are crucial for the movement and interaction of dendritic cells and T cells, supporting effective T cell responses through structural and functional cues [7]. - The research indicates that m11 protein from mouse cytomegalovirus (MCMV) targets FRC networks and disrupts the key function of CD44, inhibiting antiviral immunity [8][10]. Group 2: Implications of Findings - The findings suggest a new mechanism of viral immune evasion, fundamentally altering the understanding of signals that shape immune function [5]. - CD44 is identified as an essential molecule for the normal operation of the FRC network, highlighting a previously unrecognized matrix-based mechanism critical for effective T cell responses [9]. Group 3: Potential Therapeutic Applications - The study implies that insights gained from viral mechanisms could inform the design of therapeutic molecules targeting CD44 to mitigate excessive immune activation in autoimmune diseases [11].

Core Viewpoint - The study identifies the TCR-SUB1-DOCK2 signaling axis as a crucial pathway linking TCR antigen recognition signals to CD4⁺ T cell tissue migration, providing new insights into the mechanisms of autoimmune diseases and potential therapeutic targets for immune intervention strategies [5]. Group 1: Research Findings - The research team discovered that the transcription factor SUB1 is selectively upregulated in CD4⁺ T cells from autoimmune disease patients, induced by the T cell receptor (TCR)-interferon regulatory factor-4 (IRF4) signaling axis [2]. - Conditional knockout of Sub1 in T cells reduces the expression of the cell division control factor DOCK2, inhibiting Rac-dependent actin polymerization and T cell motility, thereby preventing the onset of experimental autoimmune encephalomyelitis [2]. - SUB1 forms biomolecular condensates through liquid-liquid phase separation (LLPS), opening chromatin at the Junb and Dock2 gene loci, directly activating Junb transcription, and amplifying Dock2 transcription in collaboration with JUNB [2]. Group 2: Implications for Autoimmunity - The TCR-SUB1-DOCK2 signaling axis serves as a therapeutic target focused on the migration pathways of pathogenic T cells, linking TCR signaling to cytoskeletal reorganization [2]. - This research deepens the understanding of the pathogenesis of autoimmune diseases and provides a theoretical basis and potential targets for developing precise and safe immune intervention strategies [5].

Core Insights - The research from Harvard University reveals a dual mechanism by which stress leads to hair loss, providing new insights into autoimmune diseases [1] Group 1: Mechanism of Hair Loss - The first mechanism identified is "immediate hair loss," triggered by the sympathetic nervous system's response to stress, resulting in the release of high levels of norepinephrine, which can kill rapidly proliferating cells in hair follicles [1] - The second mechanism involves the destruction of hair follicles by norepinephrine, which leads the body to perceive the damaged tissue as foreign, triggering an immune response that activates CD8+ T cells to attack hair follicles, potentially causing recurrent hair loss with lasting effects [1] Group 2: Implications for Autoimmune Diseases - This discovery is significant for understanding autoimmune diseases, as conditions like type 1 diabetes, lupus, and multiple sclerosis often require external triggers, with stress potentially being one of them [1]

Core Viewpoint - The study published in Science Translational Medicine highlights the role of the m6A demethylase FTO in the proliferation of age-associated B cells (ABC) and its connection to kidney damage in systemic lupus erythematosus (SLE), suggesting potential therapeutic targets [2][4][10]. Group 1: Mechanism of SLE and ABC Proliferation - The research identifies that the expansion of ABC in SLE is mediated by the m6A demethylase FTO, linking it to kidney damage [4]. - FTO is found to be highly expressed in ABC of SLE patients, with its expression positively correlated with immune damage in the kidneys [8]. - Overexpression of FTO in mouse and human B cells promotes ABC expansion and exacerbates SLE, while FTO deficiency improves autoimmune responses driven by ABC [9]. Group 2: TLR7-FTO-ATP6V1G1 Signaling Pathway - The study reveals that activation of the TLR7-MyD88 signaling pathway upregulates FTO expression, which in turn targets ATP6V1G1 in an m6A-dependent manner, promoting TLR7-driven ABC differentiation [9][10]. - FTO deficiency impairs lysosomal autophagy by reducing V-ATPase activity mediated by ATP6V1G1, leading to mitochondrial dysfunction in B cells [10]. - The accumulation of damaged mitochondria results in decreased oxidative phosphorylation and increased reactive oxygen species levels, inhibiting cell proliferation and ABC differentiation [10].

Core Viewpoint - Atrial Fibrillation (AF) is the most common persistent arrhythmia, leading to significant morbidity and mortality due to heart failure and thromboembolic strokes. There is an urgent need for better understanding of the pathways that trigger AF to develop effective and safe treatments [2]. Group 1: Research Findings - A study published by researchers from Harvard Medical School indicates that B cells promote atrial fibrillation through the production of autoantibodies in mice with typical AF risk factors such as hypertension, obesity, and mitral regurgitation [3]. - The use of anti-CD20 monoclonal antibodies to target and deplete B cells significantly reduced the incidence of AF in the HOMER mouse model, suggesting a new therapeutic avenue for patients with autoantibody-induced AF [6][9]. Group 2: Mechanisms of Action - In the HOMER mouse model, dendritic cells and B cells were found to expand in the left atrium and cardiac draining lymph nodes, with myocardial cell-derived proteins detected in these areas. Systemic expansion of B cells under interferon-α stimulation led to the production of autoantibodies that impaired calcium handling in myocardial cells [6]. - The depletion of B cells or inhibition of plasma cell maturation resulted in a significant reduction in the likelihood of AF being induced, highlighting the role of these immune cells in the pathophysiology of AF [7].

Core Viewpoint - The article discusses the significance of the 2025 Nobel Prize in Physiology or Medicine awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking work on regulatory T cells (Treg cells) and their role in immune tolerance, which has profound implications for understanding autoimmune diseases and cancer escape mechanisms [3][35]. Group 1 - The Nobel Prize was awarded for the discovery and definition of CD4+ CD25+ FOXP3+ regulatory T cells (Treg cells) and their importance in controlling self-reactive responses, marking a new field of research in peripheral immune tolerance [3][35]. - The research highlights the collaborative effort and curiosity in science, leading to a transformative understanding of immune regulation [3][35]. - The findings have significant implications for the treatment of autoimmune diseases and cancer, emphasizing the potential of Treg cells in clinical applications [35]. Group 2 - Mary Brunkow expressed her surprise at receiving the Nobel Prize, reflecting on the teamwork involved in their research and the changes in her scientific career since then [14][24]. - Fred Ramsdell shared a humorous account of how he learned about his award while camping, illustrating the unexpected nature of the recognition [23][24]. - Shimon Sakaguchi emphasized the importance of persistence in research, stating that the discovery of Treg cells was a result of continuous exploration despite challenges in the field [33][35]. Group 3 - The article highlights the collaboration between biotechnology and academic sectors, showcasing how such partnerships can lead to significant advancements in medical treatments [29][30]. - The historical context of the research is noted, with the original findings based on a mutant mouse model that exhibited severe autoimmune phenotypes, underscoring the importance of foundational research [30][31]. - The recognition of their work is seen as a motivation for further exploration and application of Treg cells in treating various immune diseases and improving organ transplant outcomes [35].

Core Viewpoint - The research identifies loss-of-function mutations in the PLD4 gene as a cause of systemic lupus erythematosus (SLE), providing a theoretical basis for precise diagnosis and treatment of the disease [3][10]. Group 1: Research Findings - The study published in Nature confirms that mutations in the PLD4 gene can lead to SLE and elucidates the pathogenic mechanism involved [3]. - The research team reported five SLE patients with renal lesions exhibiting PLD4 biallelic mutations [8]. - PLD4 is highly expressed in dendritic cells, monocytes, and B cells, and functions as a 5' nucleic acid exonuclease that limits the overactivation of TLR7 and TLR9 [7]. Group 2: Mechanism of Action - TLR7 and TLR9 play critical roles in sensing RNA and DNA, initiating downstream inflammatory signaling pathways that contribute to SLE development [6]. - The absence of PLD4 leads to excessive activation of TLR7 and TLR9, resulting in heightened inflammatory responses and the production of autoantibodies [10]. Group 3: Potential Therapeutic Implications - PLD4-deficient mice exhibited autoimmune phenotypes and responded to the JAK inhibitor baricitinib, suggesting that targeting type I interferon may be a potential therapy for SLE patients with PLD4 deficiency [10].

Core Viewpoint - The discussion emphasizes the importance of understanding autoimmune diseases, particularly lupus and antiphospholipid syndrome, and highlights advancements in treatment options, including cell therapy, which can significantly improve patients' quality of life and reproductive outcomes [1][30][36]. Group 1: Autoimmune Diseases Overview - There are over a hundred types of autoimmune diseases, affecting a significant population, yet awareness remains low [3]. - Common autoimmune diseases include lupus, antiphospholipid syndrome, and arthritis, with a notable prevalence among women [4][14]. - Patients often form support groups to share experiences and encourage each other, especially regarding expensive treatments [4][18]. Group 2: Patient Experience and Treatment - The role of physicians extends beyond treatment; they provide emotional support and guidance to help patients navigate their conditions [7][10]. - Many patients initially experience anxiety and uncertainty about their conditions, but with ongoing care, they often become more at ease [7][12]. - The importance of accurate diagnosis and treatment plans is emphasized, particularly in managing conditions like antiphospholipid syndrome, which can significantly impact pregnancy outcomes [16][23]. Group 3: Advances in Treatment - Cell therapy shows promise in treating autoimmune diseases by specifically targeting B cells, potentially leading to long-term remission [30][33]. - New biological agents, particularly monoclonal antibodies, are emerging as effective treatments for lupus and other autoimmune conditions [35]. - The success rate for lupus patients achieving healthy pregnancies has improved significantly, with over 80% of children born to lupus patients being healthy [28][36]. Group 4: Misconceptions and Patient Education - There is a tendency for patients to self-diagnose with conditions like antiphospholipid syndrome due to its treatable nature, which can lead to over-treatment and misinformation [21][22]. - The need for standardized antibody testing across different regions is highlighted to ensure accurate diagnosis and treatment [24]. - Patients are encouraged to maintain a balanced lifestyle and not to overly focus on their autoimmune conditions, as this can lead to unnecessary anxiety [50][53].

Core Insights - The innovative drug market in China is experiencing significant growth, with the total amount of License out transactions for innovative drugs expected to reach nearly $66 billion by the first half of 2025, surpassing the total BD transaction amount for 2024 [1] - The immune system drug market is the second largest prescription drug market globally, with an increasing share of BD transactions, particularly in the autoimmune disease sector, which is gaining attention due to unmet medical needs [2][23] - The emergence of bispecific antibodies (dual antibodies) in the autoimmune disease field is anticipated to create new blockbuster drugs, as they can target multiple antigens simultaneously, enhancing treatment efficacy [7][8][23] Group 1: Market Dynamics - The market for autoimmune disease treatments is projected to reach $119.35 billion by 2027, driven by high demand and long treatment cycles for conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [2] - The TNFα inhibitors, particularly AbbVie's Humira, have generated over $200 billion in revenue over its lifecycle, showcasing the potential for successful drug development in the immune market [2][4] - The competition in the immune drug market is intensifying, with a growing number of patented drugs and a shift towards precision medicine in clinical and commercial strategies [5] Group 2: Bispecific Antibodies - Bispecific antibodies are gaining traction in autoimmune disease treatment, with the ability to simultaneously target different antigens, potentially leading to more effective disease management [7][8] - Clinical data from Roche's bispecific antibody shows significant efficacy in treating refractory SLE patients, indicating the potential of this class of drugs in the autoimmune sector [8] Group 3: Company Insights - Kangnuo Pharmaceutical is positioned as a leading player in the autoimmune field, with its core product CM310 being the first domestically approved IL-4Rα antibody, currently in the commercialization stage [13][23] - The success of CM310 in the market is contingent on its inclusion in the medical insurance negotiation, which is crucial for its sales growth [16][23] - Kangnuo's innovative approach through the NewCo model for licensing out its products has proven beneficial, providing cash flow support and reducing risks for the company [22][23] Group 4: Future Outlook - The potential for Kangnuo's CM310 to achieve significant sales in the Chinese market is optimistic, with projections suggesting it could reach nearly $5 billion by 2030 if it successfully navigates the insurance landscape [23] - The company's advancements in the ADC drug CMG901 for cancer treatment are also noteworthy, with clinical progress ahead of competitors [19][23]